KALV
Kalvista Pharmaceuticals Inc
NASDAQ · Biotechnology
$14.90
+0.50 (+3.47%)
Open$14.78
Previous Close$14.40
Day High$15.07
Day Low$14.48
52W High$19.00
52W Low$8.84
Volume—
Avg Volume775.6K
Market Cap753.14M
P/E Ratio—
EPS$-2.95
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+334.6% upside
Current
$14.90
$14.90
Target
$64.76
$64.76
$35.35
$64.76 avg
$75.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 272.43M | 275.70M | 294.93M |
| Net Income | -77,974,346 | -85,417,882 | -94,496,772 |
| Profit Margin | -28.6% | -31.0% | -32.0% |
| EBITDA | -125,574,606 | -125,457,307 | -124,623,061 |
| Free Cash Flow | -59,177,907 | -68,220,346 | -69,677,831 |
| Rev Growth | +3.3% | +15.2% | -10.0% |
| Debt/Equity | 0.07 | 0.09 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |